Inspira’s competitive advantage is not in the art100 (acmo device) but in my opinion it is only a well-known product in the market that flows money to the company, until the introduction of its big product art500 which knows how to oxygenate blood in a unique and non-invasive way in the body, which is the main uniqueness of the company in addition to the product to which the hyle blood sensor connects
I did a bit more reading and couldn’t identify what specific advantages the ART500 has over other ECMO devices. It’s just a better version? Or can it be used for a certain patients that current ECMO devices cannot?
This is a fledgling medical device company that is going to be hit or miss. There’s lots of positives being in the companies presentation but I’m not seeing enough substance to make me a believer (yet). The fact that they don’t have earnings calls doesn’t help.
My understanding is that the term “invasive” in this context refers to the tube inserted into your trachea as part of mechanical ventilation, also known as intubation. A lot of complications can arise from this procedure.
Other types of mechanical ventilation using face masks (without intubation) for instance are considered non-invasive, even though face masks also have their own problems.
All ECMO devices are thus considered non-invasive although they do use cannulae to interface with your bloodstream. I guess cannulae are not considered invasive.